Journal of Clinical Endocrinology & Metabolism, Vol 78, 693-698, Copyright © 1994 by Endocrine Society

ARTICLES

Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man

E Ghigo, E Arvat, L Gianotti, BP Imbimbo, V Lenaerts, R Deghenghi and F Camanni
Department of Clinical Pathophysiology, University of Turin, Italy.

We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers. Reference treatments were i.v. saline and GH-releasing hormone (GHRH; 1 microgram/kg). GH release (mean +/- SEM) after the i.v. dose of 1 microgram/kg hexarelin [area under the curve (AUC), 3175 +/- 506 micrograms/min.L] was about 2 times higher than that induced by 1 microgram/kg GHRH (AUC, 1544 +/- 161 micrograms/min.L; P < 0.001). Hexarelin (2 micrograms/kg, i.v.) elicited a further increase in GH levels (AUC, 4422 +/- 626 micrograms/min.L) compared to the 1 microgram/kg dose. The GH response to 2 micrograms/kg hexarelin, i.v., was very reproducible (AUC, 4016 +/- 563 vs. 3959 +/- 803 micrograms/min.L). The sc administration of hexarelin produced a dose-dependent GH response (AUC, 3180 +/- 392 and 4459 +/- 566 micrograms.min.L with 1.5 and 3 micrograms/kg, respectively). Intranasal administration of 20 micrograms/kg hexarelin induced GH release (AUC, 2642 +/- 452 micrograms/min.L) similar to that caused by 1 microgram/kg, i.v. Twenty and 40 mg hexarelin, po, produced a dose-related increase in GH levels (AUC, 2278 +/- 442 and 4079 +/- 514 micrograms/min.L). Biological bioavailabilities were 77.0 +/- 10.5%, 4.8 +/- 0.9%, and 0.3 +/- 0.1% for the sc, intranasal, and po routes, respectively. This study shows that the GH response to hexarelin administered by the i.v. route has a limited variability and is superior to the response to GHRH. The GH-releasing activity appeared to be dose dependent. Thus, hexarelin could be clinically useful to stimulate GH secretion in humans.

This article has been cited by other articles:

				A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]

				D. Le Roith, C. Bondy, S. Yakar, J.-L. Liu, and A. Butler The Somatomedin Hypothesis: 2001 Endocr. Rev., February 1, 2001; 22(1): 53 - 74. [Abstract] [Full Text]

				M. Roumi, S. Marleau, P. du Souich, T. Maggi, R. Deghenghi, and H. Ong Kinetics and Disposition of Hexarelin, A Peptidic Growth Hormone Secretagogue, in Rats Drug Metab. Dispos., January 1, 2000; 28(1): 44 - 50. [Abstract] [Full Text]

				A. Tivesten, E. Bollano, K. Caidahl, V. Kujacic, X. Y. Sun, T. Hedner, A. Hjalmarson, B.-A. Bengtsson, and J. Isgaard The Growth Hormone Secretagogue Hexarelin Improves Cardiac Function in Rats after Experimental Myocardial Infarction Endocrinology, January 1, 2000; 141(1): 60 - 66. [Abstract] [Full Text] [PDF]

				M. Korbonits, G. Kaltsas, L. A. Perry, P. Putignano, A. B. Grossman, G. M. Besser, and P. J. Trainer The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2489 - 2495. [Abstract] [Full Text]

				R. C. Jenkins, A. Meguid El Nahas, M. E. Wilkie, C. B. Brown, J. Jones, E. Ghigo, and R. J. M. Ross The Effects of Dose, Nutrition, and Age on Hexarelin-Induced Anterior Pituitary Hormone Secretion in Adult Patients on Maintenance Hemodialysis J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1220 - 1225. [Abstract] [Full Text]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				H. G. Maheshwari, A. Rahim, S. M. Shalet, and G. Baumann Selective Lack of Growth Hormone (GH) Response to the GH-Releasing Peptide Hexarelin in Patients with GH-Releasing Hormone Receptor Deficiency J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 956 - 959. [Abstract] [Full Text]

				M. Korbonits, R. A. Jacobs, S. J. B. Aylwin, J. M. Burrin, P. L. M. Dahia, J. P. Monson, J. Honegger, R. Fahlbush, P. J. Trainer, S. L. Chew, et al. Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3624 - 3630. [Abstract] [Full Text]

				A. Rahim, P. A. O’Neill, and S. M. Shalet Growth Hormone Status during Long-Term Hexarelin Therapy J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1644 - 1649. [Abstract] [Full Text]

				J. Svensson, L. Lönn, J.-O. Jansson, G. Murphy, D. Wyss, D. Krupa, K. Cerchio, W. Polvino, B. Gertz, I. Boseaus, et al. Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 362 - 369. [Abstract] [Full Text]

				R. G. Smith, L. H. T. Van der Ploeg, A. D. Howard, S. D. Feighner, K. Cheng, G. J. Hickey, M. J. Wyvratt Jr., M. H. Fisher, R. P. Nargund, and A. A. Patchett Peptidomimetic Regulation of Growth Hormone Secretion Endocr. Rev., October 1, 1997; 18(5): 621 - 645. [Abstract] [Full Text]

				E. Ghigo, E. Arvat, J. Ramunni, A. Colao, L. Gianotti, R. Deghenghi, G. Lombardi, and F. Camanni Adrenocorticotropin- and Cortisol-Releasing Effect of Hexarelin, a Synthetic Growth Hormone-Releasing Peptide, in Normal Subjects and Patients with Cushing's Syndrome J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2439 - 2444. [Abstract] [Full Text] [PDF]

				S. Loche, A. Colao, M. Cappa, J. Bellone, G. Aimaretti, G. Farello, A. Faedda, G. Lombardi, R. Deghenghi, and E. Ghigo The Growth Hormone Response to Hexarelin in Children: Reproducibility and Effect of Sex Steroids J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 861 - 864. [Abstract] [Full Text] [PDF]

				H. G. Maheshwari, S. S. Pezzoli, A. Rahim, S. M. Shalet, M. O. Thorner, and G. Baumann Pulsatile growth hormone secretion persists in genetic growth hormone-releasing hormone resistance Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E943 - E951. [Abstract] [Full Text] [PDF]